Event Details

• Poster: "Use of Transcranial Magnetic Stimulation Data in the Design of a Dose Ranging Finding Efficacy, Safety, Tolerability and Pharmacokinetics Study of XEN1101 in Patients with Focal Epilepsy." 
• Poster: "Development of XEN496, a Pediatric Immediate-Release Formulation of the Potassium Channel Opener Ezogabine." 
• Poster: "XEN393, A Novel Selective Dual Inhibitor of Nav1.2/Nav1.6 Channels Prevents Electrically-Induced Seizures in Mice and Rats."
• Poster: "Nav1.6 Selective and Nav1.2/Nav1.6 Dual Inhibitors Reduce Action Potential Firing in Mouse Cortical Pyramidal Neurons While Sparing Inhibitory Interneuron Firing."
• Poster: "Small Molecule Potentiators of Nav1.1. Increase Action Potential Firing in Fast Spiking Cortical Inhibitory Interneurons from a Mouse Model of Dravet Syndrome."

Additional posters shown in the “Genetic Epilepsies – Updates in the Science and Diagnosis” Scientific Exhibit:

• Poster: "Development of XEN496, a Pediatric Immediate-Release Formulation of the Potassium Channel Opener Ezogabine, for the Treatment of KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE)."
• Poster: "An Online Survey of Caregivers of Patients with KCNQ2 Developmental & Epileptic Encephalopathy (KCNQ2-DEE): Focus on Ezogabine."
• Poster: "A Phase 1 Study in Healthy Subjects to Assess the Safety, Tolerability and Pharmacokinetics of XEN901, a Novel, Selective Nav1.6 Sodium Channel Inhibitor for the Treatment of SCN8A-Related Epilepsy."
• Poster: "An Online Survey of Caregivers of Patients with SCN8A-Related Epilepsy."
• Poster: "Selective Sodium Channel Inhibitors and Potentiators; Pharmacology in Cortical Slices from Wild-Type and Dravet Mice."

Note: Neurocrine Biosciences, Inc. has an exclusive license to XEN901 and other pre-clinical, selective Nav1.6 and dual Nav1.2/1.6 inhibitors. All trademarks are the property of their respective owners.